Tagged with BIO

Pharma Rafael Suarez, general manager of Ferring in Mexico, explains how the Swiss biopharmaceutical company is adapting to the recent dynamics affecting both the Mexican public and private sectors. He outlines his approach to further consolidate the Mexican affiliate, increase Ferring’s clinical research investments and manufacturing presence in Mexico. When Pharmaceutical…

Pharma As President of Biopharma Activities for Merck in France, Pierre-Henry Longeray reveals how France is the third ranked affiliate after the US and Germany for the Group; how the French culture of innovation is one of the main drivers of the business; and how Merck is shifting from a pharmaceutical…

Pharma The following chart illustrates the various bottlenecks restraining the development of France’s pharmaceutical industry, including lack of investment, fewer new molecules than other European countries, disappointing performance in biological drugs, and long waiting times for drug approval. Click here to read more articles and interviews from France, and to download the…

Pharma The Managing Director of HUMAN BioPlazma, Ákos Tóth, highlights the transformational growth that the business has experienced since becoming a part of Kedrion Biopharma in 2008, while pinpointing the strategic role that the subsidiary now plays in producing and distributing the company’s lifesaving biotherapies both inside and outside of Hungary.…

Pharma Michaela Hrdlickova of Biogen elaborates on how it is the industry’s responsibility to educate all stakeholders within the Czech Republic in order to embed a health consciousness in every individual and discusses the unique referencing methods applied in the country and their resulting challenges for both industry and patient. When…

Pharma Biotest France’s Olivier Samama discusses their recent re-entry into France, their focus on homecare treatment, and their expertise in fractionation and plasma derived products. What are the objectives and goals you have been given by Dr Bernhard Ehmer and what exactly has happened in building this affiliate these last two…

Pharma The GM of France for Bristol-Myers Squibb (BMS) discusses becoming a “diversified biopharma company”, their commitment to remaining a model of excellence for other affiliates, and his personal philosophy of leadership, moulded by two decades of international experience. You started off your term with a restructuring plan for the French…

Pharma Biopharmaceutical logistics leader World Courier strives to understand their clients’ needs as early as possible, and the Italian affiliate has gone to unusual lengths, including joining the Italian biotech association, to study the developments emerging at the industry level together with other stakeholders. What have been the main changes in…

Pharma Lyonbiopole was established in 2005 as a cluster designed to support the local business community focused on infectious diseases and microbiology. Philippe Archinard, the Biopole’s president, traces the evolution of the cluster over the last decade while underscoring the critical importance of transparency and collaboration between government, industry and academia.…

Pharma Mr Kimelfeld and Ms Labat run us through the exceptional history of Lyon and the region in the life sciences field, how Lyon is considered to be the birthplace of bio industries in France, and why life sciences will remain an economic driving force of the local economy. Could you…

Pharma Gnosis is a fully vertically integrated biotech company specialized in the manufacturing and sales of fermentation raw materials and natural finished products used in the pharmaceutical, nutraceutical, cosmetic, veterinary, and agricultural industries. The business development director shares the company’s future plans to strengthen its international footprint. Given your experience, what…

Pharma Ahead of the imminent acquisition of Baxalta by Shire, country managing director Italy Fabio Andreola shares his perspective on the rare-disease environment in Italy and how Baxalta will contribute to making the new combined company the undisputed leader in the treatment of rare diseases. How would you assess the Italian…